• Wuxi Pharmatech Inc., of Shanghai, said its wholly owned subsidiary entered a supply arrangement with Pharmacyclics Inc., of Sunnyvale, Calif., for Imbruvica (ibrutinib), the mantle-cell lymphoma therapy approved this month. Terms were not disclosed.